Literature DB >> 14632890

Carotid redo surgery: both safe and durable.

Richard A Harris1, Nicholas Stow, Charles M Fisher, Michael L Neale, Michael Appleberg.   

Abstract

AIM: To examine the outcomes and complications of surgery for recurrent carotid stenosis.
METHODS: From 1974 to 2000, 1922 carotid endarterectomies were performed in our unit. A retrospective cohort analysis of these records identified 24 patients (1.2%) who underwent surgery for recurrent stenosis.
RESULTS: There were 13 men and 11 women in the group. Median follow up was 7.2 years (interquartile range 4.4-12.4 years). The indication for redo surgery was either symptomatic severe (80-99%) or moderate (50-79%) restenosis, or severe asymptomatic (80-99%) restenosis. Repair was performed by patch angioplasty (88%), endarterectomy alone (8%) or interposition grafting (4%). Within the 30 day perioperative period there were no deaths, no strokes (major or minor), or significant cardiac morbidity. One patient (4%) developed a permanent spinal accessory nerve deficit. Another patient (4%) required further re-intervention for recurrent disease.
CONCLUSIONS: Very low surgical morbidity and mortality was achieved in our unit by implementing a policy of selective re-intervention for carotid restenosis. Redo carotid endarterectomy can therefore be recommended as having no greater morbidity than primary carotid endarterectomy. Carotid angioplasty and stenting are not recommended as a routine alternative treatment.

Entities:  

Mesh:

Year:  2003        PMID: 14632890     DOI: 10.1046/j.1445-2197.2003.t01-8-.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  1 in total

1.  Non-invasive imaging of carotid arterial restenosis using 3T cardiovascular magnetic resonance.

Authors:  Alistair C Lindsay; Luca Biasiolli; Steven Knight; Colin Cunnington; Matthew D Robson; Stefan Neubauer; James Kennedy; Ashok Handa; Robin P Choudhury
Journal:  J Cardiovasc Magn Reson       Date:  2014-01-08       Impact factor: 5.364

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.